| scholarly article | Q13442814 |
| P2093 | author name string | Jun He | |
| Jing Li | |||
| Zheng Guo | |||
| Yanhua Chen | |||
| Hao Cai | |||
| Qingzhou Guan | |||
| Wannan Chen | |||
| P2860 | cites work | Application of binomial distribution to medicine: comparison of one sample proportion to an expected proportion (for small samples). Evaluation of a new treatment. Evaluation of a risk factor | Q68446753 |
| Comparison of evaluations for hormone receptors in breast carcinoma using two manual and three automated immunohistochemical assays | Q79717696 | ||
| [New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1)] | Q82239528 | ||
| Biomarker analysis of neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone or Paclitaxel in early-stage breast cancer | Q85936187 | ||
| A qualitative transcriptional signature to reclassify estrogen receptor status of breast cancer patients | Q88154120 | ||
| TSG: a new algorithm for binary and multi-class cancer classification and informative genes selection | Q41908005 | ||
| Circumvent the uncertainty in the applications of transcriptional signatures to tumor tissues sampled from different tumor sites | Q42244798 | ||
| Breast cancer molecular subtypes respond differently to preoperative chemotherapy | Q42482998 | ||
| Molecular subtype profiling of invasive breast cancers weakly positive for estrogen receptor | Q42488655 | ||
| The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes | Q42511189 | ||
| Rank-based predictors for response and prognosis of neoadjuvant taxane-anthracycline-based chemotherapy in breast cancer | Q44283854 | ||
| Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. | Q46765380 | ||
| Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer | Q46771645 | ||
| Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. | Q46966638 | ||
| Robust transcriptional signatures for low-input RNA samples based on relative expression orderings. | Q47093769 | ||
| Quantitative or qualitative transcriptional diagnostic signatures? A case study for colorectal cancer | Q49247828 | ||
| Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. | Q51935846 | ||
| Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer. | Q51943531 | ||
| Predictive value of neoadjuvant chemotherapy failure in breast cancer using FDG-PET after the first course. | Q53194326 | ||
| American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. | Q55154696 | ||
| A new muscle journal for the nineties | Q67895737 | ||
| Global cancer statistics | Q22241238 | ||
| Preoperative chemotherapy for women with operable breast cancer | Q24245281 | ||
| Classifying gene expression profiles from pairwise mRNA comparisons | Q24681960 | ||
| Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 | Q27861047 | ||
| Effect of training-sample size and classification difficulty on the accuracy of genomic predictors | Q33892880 | ||
| Relative expression analysis for molecular cancer diagnosis and prognosis | Q34066558 | ||
| Gene-expression profiling for rejection surveillance after cardiac transplantation | Q34111639 | ||
| Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer. | Q34275072 | ||
| Revisiting global gene expression analysis | Q34308389 | ||
| International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations | Q35164084 | ||
| Female breast cancer incidence and mortality in 2011, China | Q35909226 | ||
| Impact of collection and storage of lung tumor tissue on whole genome expression profiling | Q36539946 | ||
| Identifying clinically relevant drug resistance genes in drug-induced resistant cancer cell lines and post-chemotherapy tissues | Q36562337 | ||
| Genomic grade index is associated with response to chemotherapy in patients with breast cancer | Q37278382 | ||
| Robust transcriptional tumor signatures applicable to both formalin-fixed paraffin-embedded and fresh-frozen samples | Q37701656 | ||
| Do predictive signatures really predict response to cancer chemotherapy? | Q37819795 | ||
| A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. | Q39751877 | ||
| Critical limitations of prognostic signatures based on risk scores summarized from gene expression levels: a case study for resected stage I non-small-cell lung cancer | Q40646057 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | doxorubicin | Q18936 |
| paclitaxel | Q423762 | ||
| P304 | page(s) | 34 | |
| P577 | publication date | 2020-03-25 | |
| P1433 | published in | Frontiers in molecular biosciences | Q27726420 |
| P1476 | title | A Qualitative Transcriptional Signature for Predicting Extreme Resistance of ER-Negative Breast Cancer to Paclitaxel, Doxorubicin, and Cyclophosphamide Neoadjuvant Chemotherapy | |
| P478 | volume | 7 |
Search more.